ALVR Allovir Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALVR

Price (delayed)

$0.7862

Market cap

$90.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.66

Enterprise value

$22.16M

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative ...

Highlights
The quick ratio has soared by 183% since the previous quarter and by 126% year-on-year
Allovir's debt has decreased by 46% YoY and by 33% from the previous quarter
The net income is down by 8% year-on-year but it is up by 6% since the previous quarter
The equity has declined by 38% year-on-year and by 17% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.allovir.com
Peers: OMGA ONCT

Key stats

What are the main financial stats of ALVR
Market
Shares outstanding
115M
Market cap
$90.42M
Enterprise value
$22.16M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.75
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$179.66M
EBITDA
-$171.84M
Free cash flow
-$136.71M
Per share
EPS
-$1.66
Free cash flow per share
-$1.19
Book value per share
$1.05
Revenue per share
$0
TBVPS
$1.26
Balance sheet
Total assets
$144.14M
Total liabilities
$23.7M
Debt
$18.34M
Equity
$120.44M
Working capital
$133.83M
Liquidity
Debt to equity
0.15
Current ratio
18.48
Quick ratio
18.43
Net debt/EBITDA
0.4
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-82.9%
Return on equity
-104%
Return on invested capital
-177.6%
Return on capital employed
-131.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALVR stock price

How has the Allovir stock price performed over time
Intraday
2.1%
1 week
6.24%
1 month
3.45%
1 year
-74.8%
YTD
15.65%
QTD
9.19%

Financial performance

How have Allovir's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$188.97M
Net income
-$179.53M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 10% YoY but it has grown by 5% from the previous quarter
The net income is down by 8% year-on-year but it is up by 6% since the previous quarter

Growth

What is Allovir's growth rate over time

Valuation

What is Allovir stock price valuation
P/E
N/A
P/B
0.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALVR's EPS is up by 17% YoY and by 9% QoQ
The equity has declined by 38% year-on-year and by 17% since the previous quarter
The price to book (P/B) is 27% less than the last 4 quarters average of 1.0

Efficiency

How efficient is Allovir business performance
Allovir's return on invested capital has shrunk by 65% YoY and by 10% QoQ
ALVR's return on equity is down by 30% year-on-year and by 4.3% since the previous quarter
The return on assets has declined by 27% year-on-year and by 5% since the previous quarter

Dividends

What is ALVR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALVR.

Financial health

How did Allovir financials performed over time
The quick ratio has soared by 183% since the previous quarter and by 126% year-on-year
The current ratio has soared by 180% from the previous quarter and by 117% YoY
Allovir's debt is 85% less than its equity
Allovir's debt has decreased by 46% YoY and by 33% from the previous quarter
The equity has declined by 38% year-on-year and by 17% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.